Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2021-01-12 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
2020年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2020 annual performance forecast (业绩预告) for Anhui Anke Biotechnology (Group) Co., Ltd. It covers the full fiscal year 2020 and provides estimated net profit growth percentages and explanations for performance changes. The document explicitly states that the financial data is preliminary and unaudited, and that detailed audited data will be disclosed in the 2020 annual report. The document length is short (984 characters) and it is an announcement of expected financial results, not the full annual report itself. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. FY 2020
2021-01-12 Chinese
关于注射用重组人生长激素新增适应症申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Anhui Anke Biotechnology Group Co., Ltd. regarding the acceptance of a new indication application for their recombinant human growth hormone by the National Medical Products Administration. It provides details about the new indication, regulatory acceptance numbers, and background information on the condition treated. The document is only 1277 characters long and does not contain any financial data, financial statements, or detailed report content. It is clearly an announcement about a regulatory acceptance related to a product indication, not a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-01-11 Chinese
国元证券股份有限公司关于公司2020年持续督导培训情况的报告
Audit Report / Information Classification · 85% confidence The document is a report from a sponsoring institution (Guoyuan Securities Co., Ltd.) about continuous supervision training conducted in 2020 for Anhui Anke Bioengineering (Group) Co., Ltd. It details the training content, participants, and summary of the training session. The document is not a financial report, audit, earnings release, or any form of regulatory filing related to financial results or corporate governance changes. It is a specific report on a training activity related to regulatory compliance and supervision. This type of document does not fit into categories like Annual Report, Interim Report, or Regulatory Filings. It is a specialized report related to ongoing supervision and training by the sponsor institution, which aligns best with Audit Report / Information (AR) as it relates to regulatory compliance and oversight activities rather than financial results or governance changes. FY 2020
2021-01-11 Chinese
关于参与出资设立产业基金的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the progress of participating in the establishment of an industrial fund. It includes details about the board meeting approval, the fund's registration with the Asset Management Association of China, and the receipt of the private equity fund filing certificate. The document is short (901 characters) and primarily serves as a progress update and regulatory announcement about the fund setup and filing, without containing financial statements or detailed financial data. It does not fit into categories like Annual Report, Interim Report, or Capital/Financing Update since it is not a full report or detailed financial disclosure but rather a regulatory progress announcement. Therefore, it best fits the category of Regulatory Filings (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-12-24 Chinese
关于第七届董事会第六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the sixth meeting of the seventh board of directors of Anhui Anke Biotechnology Engineering (Group) Co., Ltd. It details the approval of a proposal related to the transfer of part of the equity of a wholly-owned subsidiary for employee stock incentives. The document includes voting results and references a related announcement published on a regulatory disclosure website. The content focuses on board decisions and management authorization rather than financial results or detailed reports. The document length is short (975 characters), and it is a formal announcement of board meeting resolutions, which fits the category of Board/Management Information (MANG).
2020-12-15 Chinese
关于筹划转让全资子公司部分股权用以股权激励的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Anhui Anke Biological Engineering (Group) Co., Ltd. regarding the planning of transferring part of the equity of its wholly-owned subsidiary for the purpose of equity incentives. It details the board meeting resolution, the subsidiary's basic information, the purpose of the equity transfer, and the potential impact on the company. The document is an announcement of a corporate action related to capital structure changes (equity transfer for employee incentives). It is not a full financial report, audit, or earnings release, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it concerns fundraising and capital structure changes through equity transfer for incentives.
2020-12-15 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.